ClinicalTrials.gg
CompletedNCT05073835BARI-STEPUpdated Oct 26, 2026Results posted

Semaglutide 2.4 mg in Patients With Poor Weight-loss

A Phase 3 interventional study of Semaglutide 3 mg and Placebo in Obesity, Diabetes and Metabolic Syndrome, sponsored by University College, London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 26, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.

Enrollment
91st of 145
70 · median 100
Started
2022
with 18 others
Phase 3
43 of 145
11 open now
Registered
34th of 145
by date

Among the 145 studies testing semaglutide in Obesity, this one is the 91st largest by enrollment, is one of 19 that started in 2022, is one of 43 in phase 3, and was the 34th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

65 more — sign in →

By country, each count listing its studies:

All 70 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.

03

Conditions studied

  • Obesity
  • Diabetes
  • Metabolic Syndrome

Keywords

  • obesity
  • diabetes
  • semaglutide
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients, ≥1 year primary GB or primary SG, with poor weight-loss (\<20% WL) that is not caused by either a surgical or psychological problem.
  2. Adults, 18-65 years inclusive.
  3. Females of and female partners of male participants must be willing to use highly effective method of (hormonal or barrier method of birth control; abstinence) (Appendix 2) from the time consent is signed until 2 months after treatment discontinuation.
  4. Females of childbearing potential must have a negative pregnancy test within 7 days prior to randomisation. NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are .
  5. A self-reported ≤5 % variation in body weight over preceding 3 months.
  6. Fluent in English and able to understand and complete questionnaires.
  7. Participants capable to provide written and comply with the trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Bariatric surgical procedure other than GB and SG, or revision bariatric surgery of any operation type.
  2. Personal history of type I diabetes or type II diabetes mellitus currently treated with insulin.
  3. Concomitant use of GLP-1R agonist or DPPIV-inhibitors.
  4. Female who is pregnant, breast-feeding, or intends to become pregnant.
  5. Current participation in other clinical intervention trial.
  6. History of suicidal attempt in the previous 5 years or untreated severe depression or mental health condition assessed by direct questioning.
  7. Symptomatic gallstone disease
  8. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).
  9. Renal impairment measured as glomerular infiltration rate ( \<15 ml/min 1.73 m2
  10. Known or suspected to semaglutide or any of the involved in their formulation.
  11. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  12. History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
  13. Personal history of acute pancreatitis 180 days before screening or chronic pancreatitis.
  14. Uncontrolled thyroid disease.
  15. History of stroke, unstable angina, acute coronary syndrome, congestive heart failure class III-IV within the preceding 12 months.
  16. Untreated arrhythmias.
  17. Diabetic gastroparesis.
  18. Concomitant usage of medications that cause weight gain or weight loss.
  19. Known or suspected abuse of alcohol or recreational drugs.
  20. Severe hepatic impairment diagnosed via liver function blood tests and clinical evaluation
  21. Any additional factor, which in the investigator's opinion, might jeopardise the subject's safety or compliance with the trial protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Intervention

    Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.

    Drug: Semaglutide 3 mg

  • Placebo comparator
    Control

    Placebo administration, once weekly, subcutaneous injection.

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Weight Change

    Weight change = \[(Weight at Visit 68 minus weight at baseline)/ weight at baseline\]\*100. Positive values represent weight gain and negative values represent weight loss.

    Time frame: Baseline and week 68

Secondary outcomes

  1. Categorical Weight Loss

    Cumulative percentage of participants who met the criteria for each weight loss threshold (\<10%, ≥10%, ≥15%, ≥20%) at 68 weeks

    Time frame: Baseline to 68 weeks

  2. Body Mass Index (BMI)

    Change in Body Mass Index from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

  3. Body Composition

    Change in body composition (measured by Bioelectrical Impedance Analysis) from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

  4. Blood Pressure Change

    Change in systolic and diastolic Blood Pressure from baseline to 68 weeks. Blood pressure change = Week 68 value minus Baseline value

    Time frame: Baseline to 68 weeks

  5. Cardiovascular Outcome - Heart Rate

    Change in heart rate from baseline to 68 weeks

    Time frame: baseline to 68 weeks

  6. HbA1c

    Change in HbA1c from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

  7. Lipid Profile

    Mean changes in total cholesterol and triglycerides from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

  8. High-sensitivity C-reactive Protein (hsCRP)

    Mean change in High-sensitivity C-reactive protein (hsCRP) from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

  9. Change in IWQOL-Lite (Impact of Weight on Quality of Life)

    The 'Impact of Weight on Quality of Life' is a 5 point Likert scale ranging from 1 = "Never true" to 5 = "Always true". It consist of five subscales (physical function, self-esteem, sexual life, public distress and work). Average scores are computed if a minimum of 50% of the items for each scale are answered, and for the total score only if 75% of all items are completed. The average score is multiplied by the total number of items for each scale. The total score is a mean of all available items averaged together. The averaged scores are then transformed and reversed, to be from 0 lowest (worst), to 100 highest (best) quality of life. The change in IQWOL-Lite scores from baseline to 68 weeks was calculated by week 68 score minus baseline score".

    Time frame: Baseline to 68 weeks

  10. Change in Systolic Blood Pressure and Diastolic Blood Pressure in Participants With Pre-existing Hypertension

    Change in systolic and diastolic BP from baseline to 68 weeks in participants with pre-existing hypertension. Blood pressure change = Week 68 value minus Baseline value

    Time frame: Baseline to 68 weeks

  11. HbA1c in Participants With Pre-existing Type 2 Diabetes

    Change in HbA1c from baseline to 68 weeks in participants with pre-existing Type 2 Diabetes. HbA1c change = Week 68 value minus Baseline value

    Time frame: Baseline to 68 weeks

  12. Change in Circulating HbA1c Levels in Participants With Pre-diabetes

    Change in circulating HbA1c levels in participants with pre-diabetes from baseline to 68 weeks

    Time frame: Baseline to 68 weeks

07

Results

Posted Oct 26, 2026
Limitations and caveats
Limitations include a primary surgery cohort with few bypass patients. Patients did not reach weight loss plateau by 68 weeks, indicating a longer treatment period may be necessary to achieve maximum effect. There was limited ethnic diversity and few male patients. No data was captured on prior use of weight management pharmacotherapies and direct measurements of energy intake and physical activity was not recorded, potentially contributing to variability in weight loss between groups.

Participant flow

Participants were recruited via Bariatric Clinics across 2 London hospitals between 1 November 2022 and 02 November 2023, with follow up of the final patient on 09 April 2025.

Participant flow — Overall Study
MilestonePlaceboSemaglutide 2.4mg
Started3535
Completed2934
Not completed61
Withdrew: Adverse event11
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryPercentage Weight Change

Weight change = \[(Weight at Visit 68 minus weight at baseline)/ weight at baseline\]\*100. Positive values represent weight gain and negative values represent weight loss.

Time frame:
Baseline and week 68
Reported as:
Mean · percentage change
Percentage Weight Change
percentage changePlaceboSemaglutide 2.4mg
Percentage Weight Change0.4 ± 7.0-18.0 ± 9.2
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Mean difference (final values): -19.1 · 95% CI -23.4 to -14.8
SecondaryCategorical Weight Loss

Cumulative percentage of participants who met the criteria for each weight loss threshold (\<10%, ≥10%, ≥15%, ≥20%) at 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Number · percentage of pariticpants
Categorical Weight Loss
percentage of pariticpantsPlaceboSemaglutide 2.4mg
<10% weight loss93.114.7
≥10% weight loss6.985.3
≥15% weight loss6.961.8
≥20% weight loss3.447.1
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Chi-squared · p = <0.001
SecondaryBody Mass Index (BMI)

Change in Body Mass Index from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · Kg/m^2
Body Mass Index (BMI)
Kg/m^2PlaceboSemaglutide 2.4mg
Body Mass Index (BMI)0.03 ± 1.0-7.9 ± 1.0
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Mean difference (net): -7.9 · 95% CI -9.8 to -6.0
SecondaryBody Composition

Change in body composition (measured by Bioelectrical Impedance Analysis) from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · kg
Body Composition
kgPlaceboSemaglutide 2.4mg
Adjusted mean change in fat mass0.9 ± 2.3-15.8 ± 2.3
Adjusted mean change in lean soft mass-0.2 ± 1.2-5.5 ± 1.2
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Mean difference (net): -16.6 · 95% CI -20.8 to -12.5
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Mean difference (net): -5.3 · 95% CI -7.4 to -3.1
SecondaryBlood Pressure Change

Change in systolic and diastolic Blood Pressure from baseline to 68 weeks. Blood pressure change = Week 68 value minus Baseline value

Time frame:
Baseline to 68 weeks
Reported as:
Mean · mmHg
Blood Pressure Change
mmHgPlaceboSemaglutide 2.4mg
Adjusted mean change in Systolic blood pressure2.00 ± 3.1-3.9 ± 3.3
Adjusted mean change in Diastolic blood pressure5.85 ± 2.31.64 ± 2.5
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = 0.059 · Mean difference (net): -5.9 · 95% CI -12.0 to 0.2
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = 0.068 · Mean difference (net): -4.2 · 95% CI -8.7 to -0.3
SecondaryCardiovascular Outcome - Heart Rate

Change in heart rate from baseline to 68 weeks

Time frame:
baseline to 68 weeks
Reported as:
Mean · beats per minute (bmp)
Cardiovascular Outcome - Heart Rate
beats per minute (bmp)PlaceboSemaglutide 2.4mg
Cardiovascular Outcome - Heart Rate-6.6 ± 2.4-4.9 ± 2.7
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = 0.460 · Median difference (net): 1.8 · 95% CI -3.0 to 6.5
SecondaryHbA1c

Change in HbA1c from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · mmol/mol
HbA1c
mmol/molPlaceboSemaglutide 2.4mg
HbA1c1.7 ± 0.8-3.6 ± 0.8
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Median difference (net): -5.3 · 95% CI -6.6 to -4.0
SecondaryLipid Profile

Mean changes in total cholesterol and triglycerides from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · Mmol/l
Lipid Profile
Mmol/lPlaceboSemaglutide 2.4mg
Total cholesterol0.2 ± 0.2-0.3 ± 0.2
Triglycerides0.2 ± 0.2-0.3 ± 0.2
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = 0.014 · Mean difference (net): -0.5 · 95% CI -0.9 to -0.1
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Mean difference (net): -0.5 · 95% CI -0.8 to -0.3
SecondaryHigh-sensitivity C-reactive Protein (hsCRP)

Mean change in High-sensitivity C-reactive protein (hsCRP) from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · Mg/l
High-sensitivity C-reactive Protein (hsCRP)
Mg/lPlaceboSemaglutide 2.4mg
High-sensitivity C-reactive Protein (hsCRP)1.4 ± 1.50.4 ± 1.6
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = 0.517 · Mean difference (net): -1.0 · 95% CI -3.9 to 2.0
SecondaryChange in IWQOL-Lite (Impact of Weight on Quality of Life)

The 'Impact of Weight on Quality of Life' is a 5 point Likert scale ranging from 1 = "Never true" to 5 = "Always true". It consist of five subscales (physical function, self-esteem, sexual life, public distress and work). Average scores are computed if a minimum of 50% of the items for each scale are answered, and for the total score only if 75% of all items are completed. The average score is multiplied by the total number of items for each scale. The total score is a mean of all available items averaged together. The averaged scores are then transformed and reversed, to be from 0 lowest (worst), to 100 highest (best) quality of life. The change in IQWOL-Lite scores from baseline to 68 weeks was calculated by week 68 score minus baseline score".

Time frame:
Baseline to 68 weeks
Reported as:
Mean · scores on a scale
Change in IWQOL-Lite (Impact of Weight on Quality of Life)
scores on a scalePlaceboSemaglutide 2.4mg
Change in IWQOL-Lite (Impact of Weight on Quality of Life)9.3 ± 3.923.7 ± 4.1
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · p = <0.001 · Median difference (net): 14.3 · 95% CI 6.5 to 22.1
SecondaryChange in Systolic Blood Pressure and Diastolic Blood Pressure in Participants With Pre-existing Hypertension

Change in systolic and diastolic BP from baseline to 68 weeks in participants with pre-existing hypertension. Blood pressure change = Week 68 value minus Baseline value

Time frame:
Baseline to 68 weeks
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure and Diastolic Blood Pressure in Participants With Pre-existing Hypertension
mmHgPlaceboSemaglutide 2.4mg
Systolic Blood Pressure9.4 ± 3.8-2.2 ± 3.9
Diastolic Blood Pressure7.9 ± 2.96.3 ± 3.2
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · Mean difference (net): -11.6
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · Median difference (net): -1.7
SecondaryHbA1c in Participants With Pre-existing Type 2 Diabetes

Change in HbA1c from baseline to 68 weeks in participants with pre-existing Type 2 Diabetes. HbA1c change = Week 68 value minus Baseline value

Time frame:
Baseline to 68 weeks
Reported as:
Mean · mmol/mol
HbA1c in Participants With Pre-existing Type 2 Diabetes
mmol/molPlaceboSemaglutide 2.4mg
HbA1c in Participants With Pre-existing Type 2 Diabetes4 ± 1.5-3.4 ± 1.8
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · Mean difference (net): -7.4
SecondaryChange in Circulating HbA1c Levels in Participants With Pre-diabetes

Change in circulating HbA1c levels in participants with pre-diabetes from baseline to 68 weeks

Time frame:
Baseline to 68 weeks
Reported as:
Mean · Mmol/mol
Change in Circulating HbA1c Levels in Participants With Pre-diabetes
Mmol/molPlaceboSemaglutide 2.4mg
Change in Circulating HbA1c Levels in Participants With Pre-diabetes0.2 ± 1.6-8.0 ± 2.3
Statistical analysis
  • Placebo vs Semaglutide 2.4mg · Regression, Linear · Median difference (net): -8.3

Adverse events

Collected over 74 weeks (68 weeks of treatment and 6 week wash out period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/35 (0%)8/35 (22.9%)33/35 (94.3%)
Semaglutide 2.4mg0/35 (0%)3/35 (8.6%)34/35 (97.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboSemaglutide 2.4mg
PancreatitisHepatobiliary disorders2/350/35
Gastro-oesophageal reflux diseaseGastrointestinal disorders1/350/35
Fractured patellaMusculoskeletal and connective tissue disorders1/350/35
Rupture of right quadriceps tendonMusculoskeletal and connective tissue disorders1/350/35
GallstonesHepatobiliary disorders1/350/35
Spontaneous bruisingBlood and lymphatic system disorders0/351/35
Acute Coronary SyndromeCardiac disorders1/350/35
Abdominal wall abscessGastrointestinal disorders0/351/35
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/350/35
BradycardiaCardiac disorders1/350/35
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboSemaglutide 2.4mg
otherGeneral disorders29/3530/35
NauseaGastrointestinal disorders8/3524/35
DiarrhoeaGastrointestinal disorders14/3521/35
Decreased appetiteGastrointestinal disorders4/3515/35
Upper respiratory tractInfections and infestations10/3514/35
HeadacheNervous system disorders10/3514/35
ConstipationGastrointestinal disorders8/3513/35
DizzinessGastrointestinal disorders5/3512/35
FatigueGeneral disorders10/3512/35
VomitingGastrointestinal disorders6/3510/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboSemaglutide 2.4mgTotal
<=18 years000
Between 18 and 65 years353570
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboSemaglutide 2.4mgTotal
Mean47.7 ± 10.346.9 ± 10.447.3 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSemaglutide 2.4mgTotal
Female283058
Male7512
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSemaglutide 2.4mgTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American10616
White212647
More than one race415
Unknown or Not Reported000
Bodyweight (kg)
Bodyweight (kg)(units on scale)PlaceboSemaglutide 2.4mgTotal
Mean111.4 ± 19.3118.6 ± 23.3115 ± 12.6
Body Mass Index
Body Mass Index(kg/m^2)PlaceboSemaglutide 2.4mgTotal
Mean40.2 ± 642.8 ± 6.841.5 ± 6.5
Procedure Type
Procedure Type(Participants)PlaceboSemaglutide 2.4mgTotal
Sleeve gastrectomy282755
Gastric bypass7815
Time Since Surgery
Time Since Surgery(months)PlaceboSemaglutide 2.4mgTotal
Mean79.1 ± 34.288.6 ± 50.583.9 ± 43.1

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Janine Makaronids
    London, WC1E 6JF, United Kingdom
09

References and documents

Publications

  • Stanley C, Mallik R, Hamid N, Jassil FC, Reuven V, Ruwona T, Dicken SJ, Qamar S, Norton B, Kingett H, Pucci A, Magee C, Boniface D, Batterham RL, Devalia K, Mok J, Elkalaawy M, Loy J, Jenkinson A, Markakis H, Adamo M, Brown A, Makaronidis J. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. Nat Med. 2026 Jul;32(7):2662-2672. doi: 10.1038/s41591-026-04416-4. Epub 2026 May 22. PubMed 42174253 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Apr 2025, 29 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's 29 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2025 → Apr 2025 and completion Sep 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Oct 12, 2021
StartActual
Nov 1, 2022
Primary completionActual
Apr 9, 2025was Mar 2025
CompletionActual
Apr 9, 2025was Sep 2025
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 26, 2026
Results
Results posted
posted Oct 26, 2026
Primary completion
Mar 2025→Apr 9, 2025 (actual)
Oct 26, 2026
Study completion
Sep 2025→Apr 9, 2025 (actual)
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Weight lossNow Percentage Weight ChangeTime frame: 68 weeks → Baseline and week 68
Oct 26, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42174253 ↗
Oct 26, 2026
Secondary outcomes
3 edited, 9 added, 11 removed
What changed in the outcomes
  • EditedChange in circulatingCirculating HbA1c levelsLevels in Participants With Pre-diabetesTime frame: 68 weeks → Baseline to 68 weeks
  • EditedChangeHbA1c in circulating HbA1c levels in participants with pre-diabetes at baselineParticipants With Pre-existing Type 2 DiabetesTime frame: 68 weeks → Baseline to 68 weeks
  • EditedChange in Systolic Blood Pressure and diastolic BPDiastolic Blood Pressure in participants with preParticipants With Pre-existing hypertensionHypertensionTime frame: 68 weeks → Baseline to 68 weeks
  • AddedCategorical Weight LossTime frame: Baseline to 68 weeks
  • AddedBody Mass Index (BMI)Time frame: Baseline to 68 weeks
  • AddedBody CompositionTime frame: Baseline to 68 weeks
  • AddedBlood Pressure ChangeTime frame: Baseline to 68 weeks
  • AddedCardiovascular Outcome - Heart RateTime frame: baseline to 68 weeks
  • AddedHbA1cTime frame: Baseline to 68 weeks
  • AddedLipid ProfileTime frame: Baseline to 68 weeks
  • AddedHigh-sensitivity C-reactive Protein (hsCRP)Time frame: Baseline to 68 weeks
  • AddedChange in IWQOL-Lite (Impact of Weight on Quality of Life)Time frame: Baseline to 68 weeks
  • Removedbody weight reduction ≥10%Time frame: 68 weeks
  • Removedbody weight reduction ≥15%Time frame: 68 weeks
  • Removedbody weight reduction ≥20%Time frame: 68 weeks
  • RemovedChange in circulating HbA1c levels in participants with T2D at baselineTime frame: 68 weeks
  • RemovedSystolic and diastolic BPTime frame: 68 weeks
  • Removedpharmacological agents required for the management of hypertensionTime frame: 68 weeks
  • RemovedChange in circulating lipidsTime frame: 68 weeks
  • RemovedChange in circulating HsCRP and inflammatory cytokinesTime frame: 68 weeks
  • RemovedChanges in food craving scores assessed through power of food questionnaireTime frame: 68 weeks
  • RemovedChanges in HRQoLTime frame: 68 weeks
  • RemovedGLP-1 levelsTime frame: 68 weeks
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Completed
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42174253 ↗
    Primary completion Mar 2025→Apr 9, 2025 (now actual)
    Study completion Sep 2025→Apr 9, 2025 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Weight lossNow Percentage Weight ChangeTime frame: 68 weeks → Baseline and week 68
    Secondary outcomes 3 edited, 9 added, 11 removed
    What changed in the outcomes
    • EditedChange in circulatingCirculating HbA1c levelsLevels in Participants With Pre-diabetesTime frame: 68 weeks → Baseline to 68 weeks
    • EditedChangeHbA1c in circulating HbA1c levels in participants with pre-diabetes at baselineParticipants With Pre-existing Type 2 DiabetesTime frame: 68 weeks → Baseline to 68 weeks
    • EditedChange in Systolic Blood Pressure and diastolic BPDiastolic Blood Pressure in participants with preParticipants With Pre-existing hypertensionHypertensionTime frame: 68 weeks → Baseline to 68 weeks
    • AddedCategorical Weight LossTime frame: Baseline to 68 weeks
    • AddedBody Mass Index (BMI)Time frame: Baseline to 68 weeks
    • AddedBody CompositionTime frame: Baseline to 68 weeks
    • AddedBlood Pressure ChangeTime frame: Baseline to 68 weeks
    • AddedCardiovascular Outcome - Heart RateTime frame: baseline to 68 weeks
    • AddedHbA1cTime frame: Baseline to 68 weeks
    • AddedLipid ProfileTime frame: Baseline to 68 weeks
    • AddedHigh-sensitivity C-reactive Protein (hsCRP)Time frame: Baseline to 68 weeks
    • AddedChange in IWQOL-Lite (Impact of Weight on Quality of Life)Time frame: Baseline to 68 weeks
    • Removedbody weight reduction ≥10%Time frame: 68 weeks
    • Removedbody weight reduction ≥15%Time frame: 68 weeks
    • Removedbody weight reduction ≥20%Time frame: 68 weeks
    • RemovedChange in circulating HbA1c levels in participants with T2D at baselineTime frame: 68 weeks
    • RemovedSystolic and diastolic BPTime frame: 68 weeks
    • Removedpharmacological agents required for the management of hypertensionTime frame: 68 weeks
    • RemovedChange in circulating lipidsTime frame: 68 weeks
    • RemovedChange in circulating HsCRP and inflammatory cytokinesTime frame: 68 weeks
    • RemovedChanges in food craving scores assessed through power of food questionnaireTime frame: 68 weeks
    • RemovedChanges in HRQoLTime frame: 68 weeks
    • RemovedGLP-1 levelsTime frame: 68 weeks
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05073835
Collaborators
National Institute for Health Research, United Kingdom, Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Nov 1, 2022
Primary completion
Apr 9, 2025
Completion
Apr 9, 2025
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion